Tadocizumab

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.^[1] It binds to integrin α_IIbβ₃, a fibrinogen and fibronectin receptor found on platelets. ^[2] The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.^[1]

Tadocizumab

Monoclonal antibody
Type	Fab fragment
Source	Humanized (from mouse)
Target	Integrin αIIbβ3
Clinical data
ATC code	none
Identifiers
CAS Number	339086-80-5 N
ChemSpider	none
UNII	R34T642CGV
Chemical and physical data
Formula	C2107H3252N562O673S12
Molar mass	47609.17 g·mol−1
NY (what is this?)  (verify)